Pharmacophore models for, methods of screening for, and identification of the cytochrome p-450 inhibitory potency of neurokinin-1 receptor antagonists
CA 2332208 A1 · Owner: Pfizer Products Inc. · Inventors: Ekins, Sean; Smith, Bill Joe
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to novel screening methods which enable the selection of neurokinin-1 (NK-1) receptor antagonist compounds which do not possess significant inhibitory potency towards cytochrome P450 enzymes in, particular, CYP2D6. The present invention also relates to a method of generating a, pharmacophore model for the CYP2D6 inhibitory activity of NK-1. receptor antagonist compounds; to methods for the discovery of molecules that are potential, NK-1 receptors antagonist compounds which do not possess significant inhibitory, potency towards the CYP2D6 enzyme; to methods of modeling the features of the CYP2D6 pharmacophore useful in selecting NK-1 receptor antagonist …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 24, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 24, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 24, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.